# Biopharmaceutical Research Company

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/biopharmaceutical-research-company

- Industry: Pharmaceuticals
- Headquarters: US
- Website: www.biopharmaresearchco.com
- Total disclosed funding: $10M
- Latest round: Series A (Jun 7, 2022)
- Investors on record: 6

## About

Based in California, US, and founded in 2017, Biopharmaceutical Research Company operates as a botanical cannabis firm that manufactures cannabinoid-active pharmaceutical ingredients products. In October 2022, Biopharmaceutical Research Company raised USD 20 million in series A funding led by Intrinsic Capital Partners, with participation from Achari Ventures, AFI Capital Partners, Argonautic Ventures, Delta Emerald Ventures, and Self Health Network. As of October 2022, the company is led by its CEO George Hodgin. 

Biopharmaceutical Research Company develops pharmaceutical ingredients for plant-based therapeutics for scientists and researchers conducting analytical R&D, IND application and basic clinical science. and serves the botanical cannabinoid needs of the pharmaceutical, research, and biotech communities. The company engaged in the production, extraction, and purification of botanical cannabinoid material used as API.

The company plans to use the series A funding to improve its product offerings, research, and market strategy.

## Funding rounds

- Series A, Jun 7, 2022, $10M — Self Health Network, Argonautic Ventures, Intrinsic Capital Partners, AFI Capital Partners, Delta Emerald Ventures, Achari Ventures

## Investors

- Self Health Network — Series A
- Argonautic Ventures (https://capitalatlas.ai/funds/argonautic-ventures) — Series A
- Intrinsic Capital Partners (https://capitalatlas.ai/funds/intrinsic-capital-partners) — Series A
- AFI Capital Partners (https://capitalatlas.ai/funds/afi-capital-partners) — Series A
- Delta Emerald Ventures (https://capitalatlas.ai/funds/delta-emerald-ventures) — Series A
- Achari Ventures (https://capitalatlas.ai/funds/achari-ventures) — Series A